Israeli Company Galmed Gets Positive Trial Results for Liver Drug Israeli Company Galmed Gets Positive Trial Results for Liver Drug

Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for non-alcoholic steatohepatitis (NASH), a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Related Links:

ConclusionIn conclusion, the present trial shows that supplementation with a phytosomal preparation of curcumin containing phosphatidylserine and piperine could improve glycemic factors, hepatic function and serum cortisol levels in subjects with overweight and impaired fasting glucose.
Source: European Journal of Nutrition - Category: Nutrition Source Type: research
ConclusionIn this review, I will summarize the current findings regarding the role of gut microbiome and metabolites in metabolic disorders to argue whether the current achievements may be translated into clinical practice.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research
Research, published inNutrition,Metabolism and Cardiovascular Diseases, suggests that non-alcoholic fatty liver disease increases diabetes risk in non-obese adults.Healio
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
CONCLUSIONS: The presence of comorbidities is already evident in primary school children with obesity. The effect of a lifestyle intervention on these comorbidities is greater in primary compared to secondary school children, stressing the need for early interventions. PMID: 30776292 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
Publication date: Available online 15 February 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Narendra Singh Choudhary, Ajay DusejaAbstractNon-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Patients with NAFLD are at a higher risk of developing cardiovascular disease (CVD). In fact, CVD related mortality is more common in patients with NAFLD in comparison to liver related mortality. This association is related to the common metabolic risk factors like obesity, dyslipidemia, diabetes and hypertension shared by both NAFLD and CVD, also there is independent association...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Authors: Aller R, Burgueño Gomez B, Sigüenza R, Fernández-Rodríguez C, Fernández N, Antolín B, Durà M, Pina M, Lorenzo S, García C, de Luis Román D Abstract BACKGROUND AND AIMS: non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in the western world. Although NAFLD prevalence is higher in patients with a BMI> 25 kg /m2, it is unclear if there are differences between overweight and obese patients. The associated biochemical, dietary and genetic parameters were compared between overweight and obese patients with NAFLD. ...
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
It is uncertain whether non-alcoholic fatty liver disease (NAFLD) is associated with aortic stiffness in a racial/ethnically diverse and admixed society. We addressed whether NAFLD presence and severity were associated with carotid-femoral pulse wave velocity (cf-PWV) in individuals free of cardiovascular disease.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
Current clinical care in chronic liver disease divide fatty liver disease into non-alcoholic fatty liver disease (NAFLD) or alcoholic fatty liver disease(ALD), predominantly based on alcohol intake [1]. In line with the increase in obesity NAFLD has become the leading cause of liver disease in developed countries [2,3], closely followed by ALD, which together account for the two most common liver diseases worldwide [4].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Research Article Source Type: research
Obesity often emerges in middle age, increasing risk for metabolic disorders. Our previous preclinical experiments identified that chronic exposure to non-burning ultraviolet radiation, like that achieved thro...
Source: BMC Research Notes - Category: Research Authors: Tags: Research note Source Type: research
nez-Flores R, Méndez-Cruz AR Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) is the cause of chronic liver disease. Even though NAFLD is strongly associated with obesity and metabolic syndrome, there is a proportion of patients who develop this condition in the absence of obesity and the underlying mechanisms are poorly understood. We investigated early events in the pathogenesis of non-obese NAFLD, analyzing the impact of the chronic intake of a moderate fat-enriched diet on hepatic lipid accumulation and their relationship with inflammation. Rabbits fed with a moderate Fatty-Acid- Enriched Diet 3% palm...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
More News: Alcoholism | Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Gastroenterology | Health | Israel Health | Liver | Liver Disease | Obesity | Statistics | Urology & Nephrology